相关实验视频

Updated: Jan 10, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

药物可用基因组CRISPR查识别了KEAP1/NRF2轴作为PD-L1表达的媒介

Fidan Seker-Polat¹, Magdalena Rogozinska¹, Youngho Ban²

¹Department of ObGyn, Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Chicago, IL, USA.

Communications biology

|November 19, 2025

概括

研究人员确定KEAP1/NRF2通路是癌细胞中PD-L1表达的关键调节者. 针对这一轴可能通过增强抗瘤免疫力,为癌症免疫疗法提供新的策略.

科学领域:

癌症生物学癌症生物学
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

癌细胞表达PD-L1以逃避细胞毒性T细胞的免疫攻击.
了解PD-L1的调节对于开发有效的癌症免疫疗法至关重要.

研究的目的:

确定癌细胞中细胞因子诱导的PD-L1表达的新型,可向的调节剂.
阐明控制PD-L1上调的分子机制.

主要方法:

在卵巢和胰腺癌细胞系中进行功能CRISPR基因淘汰查.
使用自定义sgRNA库准"可用药"的基因.
评估PD-L1表达变化和机械路径.

主要成果:

克里斯普尔查确定了PD-L1的已知和新型调节剂,包括CSNK1A1 (卵巢) 和CDK1 (胰腺).
在所有测试的癌症细胞系中,KEAP1的枯竭或抑制显著降低了PD-L1的表达.
KEAP1的枯竭导致NRF2的激活,该激活通过转录抑制PD-L1;NRF2调节对PD-L1水平产生反向影响.
药理性NRF2激活增强了抗瘤免疫力,并在体内减少了瘤生长.

结论:

KEAP1/NRF2轴是癌症中IFNγ介导的PD-L1表达的关键调节器.
这一途径代表了癌症免疫治疗的新且潜在的可用药物标.

更多相关视频

Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Published on: September 4, 2019

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...